Gardasil Market

HPV is a group of viruses, the composition of a family, the virus morphology is similar, but the DNA restriction enzyme map is different, the nucleocapsid protein antigenicity is different.At present, there are about 100 types of HPV identified, which are divided into cutaneous HPV and genital epithelial HPV according to the location of the infected epithelium. About 35 types can infect the female genital tract, and about 20 types are related to tumors (the HPV infections mentioned below are all female genital tract infections).Don't according to different type of HPV and the risk level of the tumor is divided into low risk type don't and high risk type HPV, low risk HPV including HPV6, 11 type, 42, 43, 44, often cause genital warts and other benign lesions including cervical intraepithelial low-grade lesions (CIN I), and high risk type HPV including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 type, and cervical cancer and cervical intraepithelial lesion (CIN II/III) related, especially HPV16 and 18 type.

Gardasil Market contains market size and forecasts of Gardasil (HPV Vaccine) in global, including the following market information:

• Global Gardasil (HPV Vaccine) Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Gardasil (HPV Vaccine) Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Gardasil (HPV Vaccine) companies in 2021 (%)

The global Gardasil (HPV Vaccine) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

HPV 2 Valent Vaccine Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gardasil (HPV Vaccine) include GSK, MSD, Walvax Biotechnology and Wantai Biological Pharmacy, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Gardasil (HPV Vaccine) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gardasil (HPV Vaccine) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Gardasil (HPV Vaccine) Market Segment Percentages, by Type, 2021 (%)

• HPV 2 Valent Vaccine
• HPV 4 Valent Vaccine
• HPV 9 Valent Vaccine

Global Gardasil (HPV Vaccine) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Gardasil (HPV Vaccine) Market Segment Percentages, by Application, 2021 (%)

• Hpv16 Type
• Hpv18 Type
• High Risk Virus (Beside Hpv16,Hpv18)
• Low Risk Virus

Global Gardasil (HPV Vaccine) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Gardasil (HPV Vaccine) Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Gardasil (HPV Vaccine) revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Gardasil (HPV Vaccine) revenues share in global market, 2021 (%)
• Key companies Gardasil (HPV Vaccine) sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Gardasil (HPV Vaccine) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GSK
• MSD
• Walvax Biotechnology
• Wantai Biological Pharmacy